期刊文献+

Ⅳ期胃癌无进展生存期分析 被引量:10

Progression-free survival analysis in patients with stage Ⅳ gastric carcinoma
暂未订购
导出
摘要 目的分析Ⅳ期胃癌无进展生存期(progression-free survival,PFS)及其影响因素。方法回顾分析2005-01~2009-12病理证实的51例Ⅳ期胃癌临床资料。主要终点指标是PFS。结果 51例患者的中位PFS2.0月(95%CI1.650-2.350)。多因素分析发现身体状况评分(ECOG评分)(HR为2.082;95%CI1.359-3.189)和姑息性化疗(HR为4.824;95%CI1.866-12.471)是影响PFS的独立因素。结论身体状况影响晚期胃癌的进展,姑息性化疗或许对晚期胃癌有益。 Objective To investigate the progression-free survival( PFS) of advanced gastric carcinoma patients and its prognostic factors. Methods The clinical data of patients histologically diagnosed as advanced gastric carcinoma were analyzed retrospectively and no prior therapy was eligible. The primary endpoint was PFS. Results The median PFS was 2. 0 months[95% confidence interval ( CI) ,1. 650-2. 350]. The multivariate analysis showed that performance status[hazard ratio( HR) =2. 082; 95%CI 1. 359-3. 189] and palliative chemotherapy( HR = 4. 824; 95% CI 1. 866-12. 471) were the independent prognostic factors for PFS. Conclusion Performance status can be used to aid the clinical decision-making. Palliative chemotherapy can be active against advanced gastric carcinoma.
出处 《山西医科大学学报》 CAS 2010年第7期591-593,共3页 Journal of Shanxi Medical University
关键词 晚期胃癌 无进展生存期 预后因素 多因素分析 advanced gastric carcinoma progression-free survival prognostic factors multivariate analysis
  • 相关文献

参考文献7

  • 1Boku N,Yamamoto S,Fukuda H,et al.Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:a randomised phase 3 study[J].Lancet Oncol,2009,10 (11):1063-1069.
  • 2Wagner AD,Grothe W,Haerting J,et al.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.
  • 3Lee SS,Lee JL,Ryu MH,et al.Combination chemotherapy with capecitabine(X)and Cisplatin (P)as first line treatment in edvanced gastric cancer:experience of 223 patients with prognostic factor analysis[J].Jpn J Clin Oncol,2007,37(1):30-37.
  • 4Chan I,Norman AR,Cunningham D,et al.Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter,randomized,controlled trials using individual patient data[J].J Clin Oncol,2004,22(12):2395-2403.
  • 5Sato Y,Takayama T,Sagawa T,et al.Phase Ⅱ study of S-1.docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J].Cancer Chemother Pharmacol,2009:Epub ahead of print.
  • 6Shah MA,Ramanathan RK,Ilson DH,et al.Multicenter phase Ⅱ study of irinotecan,cisplatin,and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J].J Clin Oncol,2006,24(33):5201-5206.
  • 7Nagashima F,Boku N,Ohtsu A,et al.Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin[J].Jpn J Clin Oncol,2005,35(12):714-719.

同被引文献67

  • 1周岱翰,林丽珠,周宜强,罗荣城,刘魁凤,贾英杰,陈继跃,牛喜伟,苏碧茹,韩慧,鲁江,张恩欣,王树堂.中西医结合治疗非小细胞肺癌近期疗效观察[J].中国中西医结合杂志,2005,25(12):1061-1065. 被引量:52
  • 2吴剑,滕国英.中药诱导肿瘤细胞凋亡的研究进展[J].国际医药卫生导报,2007,13(8):114-117. 被引量:20
  • 3Lee SY,Hwang I,Park YS,et al.Metastatic lymph node ratio in advanced gastric carcinoma:a better prognostic factor than number of metastatic lymph nodes[J]?Int J Oncol,2010,36(6):1461-1467.
  • 4Guida F,Formisano G,Esposito D,et al.Gastric cancer:surgical treatment and prognostic score[J].Minerva Chir,2008,63(2):93-99.
  • 5Boku N,Yamamoto S,Fukuda H,et al.Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:a randomised phase 3 study[J].Lancet Oncol,2009,10(11):1063-1069.
  • 6Sakurai Y,Kamoshida S,Furuta S,et al.Predictive value of orotate phosphoribosyl transferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy[J].Gan To Kagaku Ryoho,2008,35(7):1147-1155.
  • 7Wagner AD,Grothe W,Haerting J,et al.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.
  • 8Sato Y,Takayama T,Sagawa T,et al.Phase Ⅱ study of S-1,docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J].Cancer Chemother Pharmacol,2010,66(4):721-728.
  • 9Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
  • 10Okines AF,Cunningham D.Trastuzumab in gastric cancer[J].Eur J Cancer,2010,46(11):1949-1959.

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部